Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1516 to 1530 of 1688 results for carers

  1. Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]

    Discontinued [GID-TA11173]

    Technology appraisal guidance
    Discontinued

  2. Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632

    In development [GID-TA11631] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Fetal monitoring in labour (NG229)

    This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.

    NICE guideline
    Published
    14 December 2022
    View recommendations

    Sections for NG229

  4. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued [GID-TA11259]

    Technology appraisal guidance
    Discontinued

  5. Bavituximab for treating non-squamous non-small-cell lung cancer after platinum-based chemotherapy [ID975]

    Discontinued [GID-TA11260]

    Technology appraisal guidance
    Discontinued

  6. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development [GID-TA11001] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473

    In development [GID-TA11582] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    Discontinued [GID-TA11255]

    Technology appraisal guidance
    Discontinued

  9. Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

    In development [GID-HST10037] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  10. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued [GID-TA10334]

    Technology appraisal guidance
    Discontinued

  11. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    In development [GID-TA11421] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]

    In development [GID-TA11034] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    In development [GID-TA11476] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    In development [GID-TA11344] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

    In development [GID-TA11009] Expected publication date: TBC

    Technology appraisal guidance
    In development